ABSTRACT BACKGROUND A total of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchronization
pacing via an implanted coronary sinus (CS) lead is the first-line approach for achieving CRT, but 30% to 40% of patients do not respond to this conventional CRT (2) .
Furthermore, an additional 8% to 10% of eligible patients do not receive CRT due to anatomical constraints, such as the absence of appropriate CS targets, occlusion of the upper extremity venous system, phrenic nerve stimulation, or high pacing threshold in areas of diffuse scar (3, 4) . Prior approaches to achieve ventricular resynchronization in patients who have either not responded or failed CS implantation have included surgical epicardial lead placement and transseptal implantation of endocardial LV pacing leads (5) . However, surgical epicardial lead placement is inherently more invasive than the percutaneous approach, can be especially challenging in patients with prior cardiac surgery (pericardial adhesions), and is associated with lower lead survival rates compared with transvenous leads (6) . Although transseptal LV endocardial stimulation may offer the benefits of providing more physiological endocardial ventricular activation and may even be less proarrhythmic compared with epicardial LV pacing, this approach is limited by the thromboembolic risk, need for lifelong systemic anticoagulation, and concern for mechanical effects on the mitral valve.
A system that performs endocardial LV stimulation to achieve biventricular pacing, but does not require a thoracotomy or systemic anticoagulation, would be an attractive option for resynchronization therapy. In this context, a novel wireless cardiac resynchronization system (WiSE-CRT, EBR Systems, Sunnyvale, California) was developed to pace the LV endocardium with a small wireless pacing electrode. The WiSE-CRT system provides wireless pacing by transmitting acoustic (ultrasonic) energy from a pulse generator transmitter, implanted subcutaneously over the ribcage, to a receiver electrode implanted in the LV. The WiSE-CRT System functions in conjunction with a coimplanted standard right ventricular (RV) pacing system. Biventricular pacing is achieved by sensing the RV pacing output of the coimplant, followed by the system immediately transmitting acoustic energy to the electrode, thus achieving nearly simultaneous pacing of the RV and LV.
The transmitter is a phased array ultrasound system that focuses the acoustic energy on the electrode.
Herein, we present the 6-month outcomes of the prospective multicenter clinical trial of the WiSE-CRT system in the SELECT-LV (Safety and Performance of Electrodes implanted in the Left Ventricle) study.
METHODS
STUDY DESIGN. The SELECT-LV study (NCT01905670) was a multicenter (n ¼ 6 centers), prospective evaluation of the performance and safety of the WiSE-CRT System in patients indicated for CRT who had "failed" conventional CRT. Patients were eligible for inclusion if they had a standard indication for CRT and at least 1 of the following criteria: 1) "upgrades":
CS lead implantation was not advisable/feasible due to perceived risk (e.g., infection) or impediment (e.g., venous obstruction); 2) "untreated": coronary sinus lead implantation attempted but failed (e.g., difficult CS anatomy, phrenic nerve capture); or 3) "non- The global assessment score is a 7-point rating scale, allowing for the evaluation of the patient's own perspective of overall health compared with a previous point in time (9) . Positive responses to CRT between baseline and at 6 months were defined as: 1) reduction in LVESV by $15%; 2) reduction in LVEDV by $10%; 3) improvement in LVEF by $5%; and 4) improvement of NYHA functional class by $1 (3). The intrinsic and RV-paced QRS durations at baseline (pre-CRT) were compared with the intrinsic, RV-paced, and biventricular-paced QRS durations at 6 months; the delta QRS was defined as the intrinsic QRS duration (ms) at baseline minus the biventricular-paced QRS at 6 months. Secondary safety endpoints included device-related complications between 1 and 6 months. All serious adverse events were reviewed and adjudicated by an independent clinical events committee. In-person follow-up was performed at pre-discharge and at 1 week, 1 month, 2 months, and 6 months postimplant.
SYSTEM DETAILS AND IMPLANTATION. As shown in Figure 1 , the WiSE-CRT system consists of 4 components: 1) a 12-F steerable delivery catheter system with an atraumatic inflatable polyester balloon at the catheter tip; 2) an 8-F retractable delivery catheter with a pre-mounted receiver electrode (volume ¼ 0.05 ml); the electrode is an ultrasound receiver and energy converter, and is implanted in the LV via a transaortic retrograde approach; 3) a of the angular location as well as distance from transmitter to electrode is presented to the user by a graphic/data display during the site selection process.
Once an appropriate endocardial LV pacing site is identified, the electrode is deployed/anchored into the LV endocardium by advancing the catheter to push the anchor of the electrode into the endocardial surface.
Following implantation, patients were prescribed aspirin 75 to 325 mg daily throughout the study duration (6 months), and clopidogrel 75 mg daily for 3 months post-implant. For patients taking long-term warfarin therapy for other indications (e.g., atrial fibrillation, and so on), based on the center's standard practice, warfarin was permitted to be discontinued 2 to 3 days pre-procedure and reinitiated afterwards; in these long-term warfarin patients, the addition of antiplatelet agents was not required. (see the following text). The mean procedure durations for implanting the pulse generator (i.e., transmitter and battery) and pacing electrode, including time for ACT to meet the 200-to 250-s target were 85
AE 35 min and 58 AE 24 min, respectively. The optimal acoustic window for pulse generator implant was most commonly in the 6th intercostal space (60%; n ¼ 21), followed by the 7th (17%; n ¼ 6), 5th (14%; n ¼ 5) and 4th (9%; n ¼ 3) intercostal spaces. The mean distance from the transmitter to the pacing electrode was 8.5 AE 1.6 cm. 84.8%) had an improvement in the clinical composite score at 6 months, whereas a minority were either unchanged (n ¼ 3; 9.1%) or worsened (n ¼ 2; 5.9%). As shown in Table 2 , two-thirds of the patients experienced an improvement in NYHA functional class by $1 (n ¼ 22; 66.7%) and an improvement in qualityof-life scores (n ¼ 23; 69.7%). One patient was rehospitalized for HF (n ¼ 1; 3.0%) on 2 separate occasions.
As shown in Figure 2 , there were significant improvements between baseline and 6 months in (n ¼ 10), and 66% (n ¼ 21) of patients, respectively ( Figure 2D ).
An illustrative example from a patient implanted with the WiSE-CRT system, demonstrating a narrower QRS compared with RV-paced and intrinsic rhythm, and QRS shortening over time (from 1 to 6 months) is shown in Figure 3 .
SAFETY. As shown in Table 3 , the primary safety endpoint of serious procedure-or device-related events occurred in 3 patients (8.6%) within the first The other primary safety endpoint of serious procedure-or device-related events between 24 h and 1 month occurred in 8 patients (22.9%) ( Table 3) Overall, the biventricular paced QRS at 6 months was 51 ms shorter than the RV-paced QRS at baseline and 36 ms shorter than the intrinsic QRS at baseline.
These data are particularly compelling given that the enrolled cohort were largely patients who failed or were poor candidates for conventional CRT.
To date, there have been various strategies utilized to offer CRT to patients who are not candidates for conventional coronary sinus pacing. Perhaps the most 
